Baricitinib: First Global Approval
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0723-3
Abstract: Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus. JAKs transduce intracellular signals from… read more here.
Keywords: baricitinib; baricitinib first; treatment; global approval ... See more keywords
Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
Sign Up to like & getrecommendations! Published in 2022 at "Acta Dermato-Venereologica"
DOI: 10.2340/actadv.v102.1088
Abstract: Abstract is missing (Short communication) read more here.
Keywords: dermatitis baricitinib; real life; baricitinib first; treatment atopic ... See more keywords